ZVRA · NASDAQ
Zevra Therapeutics (ZVRA) Stock Price & Fundamentals
Zevra Therapeutics (ZVRA) closed at $589.02 on Oct 9, 2026, up 1.04% from the previous close of $582.93.
Share price, past year
1Y +41.02%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $589.02 |
| Sep 30, 2026 | $568.67 |
| Aug 31, 2026 | $561.88 |
| Jul 31, 2026 | $557.53 |
| Jun 30, 2026 | $534.98 |
| May 29, 2026 | $492.42 |
| Apr 30, 2026 | $485.87 |
| Mar 31, 2026 | $466.69 |
| Feb 27, 2026 | $462.40 |
| Jan 30, 2026 | $448.43 |
| Dec 31, 2025 | $450.13 |
| Nov 28, 2025 | $441.53 |
| Oct 31, 2025 | $436.77 |
Key statistics
- Market cap
- $34.95B
- P/E (TTM)
- 626.6
- EPS (TTM)
- $0.94
- Revenue (TTM)
- $136.07M
- Net income (TTM)
- $58.26M
- Shares outstanding
- 59.3M
- Dividend yield
- —
- 52-week range
- $416.78 – $589.02
Zevra Therapeutics's market cap is $34.95B, based on a share price of $589.02 and 59.3M shares outstanding as of Jun 30, 2026.
Financials
Zevra Therapeutics reported revenue of $106.47M for fiscal 2025, up 350.91% from fiscal 2024.
Zevra Therapeutics earned net income of $83.23M in fiscal 2025, a net margin of 78.2%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $106.47M | +350.9% | $83.23M | 78.2% | $1.35 | −$2.43M |
| FY2024ended Dec 31, 2024 | $23.61M | −14.0% | −$105.51M | −446.9% | −$2.28 | −$69.67M |
| FY2023ended Dec 31, 2023 | $27.46M | +170.3% | −$46.05M | −167.7% | — | −$33.83M |
| FY2022ended Dec 31, 2022 | $10.16M | −64.5% | −$26.77M | −263.5% | — | −$18.81M |
| FY2021ended Dec 31, 2021 | $28.65M | +115.6% | −$8.56M | −29.9% | −$2.11 | $10.34M |
| FY2020ended Dec 31, 2020 | $13.29M | +3.5% | −$12.76M | −96.0% | −$3.21 | −$1.97M |
| FY2019ended Dec 31, 2019 | $12.84M | — | −$24.52M | −191.0% | −$13.23 | −$23.76M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$56.47M | — | −$3.15 | −$54.22M |
| FY2015ended Dec 31, 2015 | $0.00 | — | — | — | −$7.42 | — |
| FY2014ended Dec 31, 2014 | $0.00 | — | — | — | −$10.27 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $39.66M | $8.75M | $0.14 |
| Q1 FY2026ended Mar 31, 2026 | $36.22M | $37.89M | $0.60 |
| Q4 FY2025ended Dec 31, 2025 | $34.13M | $12.17M | $0.21 |
| Q3 FY2025ended Sep 30, 2025 | $26.06M | −$544.00K | −$0.01 |
| Q2 FY2025ended Jun 30, 2025 | $25.88M | $74.71M | $1.21 |
| Q1 FY2025ended Mar 31, 2025 | $20.40M | −$3.10M | −$0.06 |
| Q4 FY2024ended Dec 31, 2024 | $12.04M | −$35.74M | — |
| Q3 FY2024ended Sep 30, 2024 | $3.70M | −$33.23M | −$0.69 |
Company profile
- Name
- Zevra Therapeutics, Inc.
- Ticker
- ZVRA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 101 Federal Street, Boston, MA 02110
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001434647
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 5, 2026
- May 6, 2026
- May 6, 2026
- Mar 16, 2026
- Mar 9, 2026
- Mar 9, 2026
Frequently asked questions
What is Zevra Therapeutics's stock price?
Zevra Therapeutics (ZVRA) closed at $589.02 on Oct 9, 2026, up 1.04% from the previous close of $582.93.
What is Zevra Therapeutics's market cap?
Zevra Therapeutics's market cap is $34.95B, based on a share price of $589.02 and 59.3M shares outstanding as of Jun 30, 2026.
How much revenue does Zevra Therapeutics make?
Zevra Therapeutics reported revenue of $106.47M for fiscal 2025, up 350.91% from fiscal 2024.
What is ZVRA's P/E ratio?
Zevra Therapeutics's price-to-earnings ratio is 626.6, based on trailing twelve-month diluted EPS of $0.94.
Does Zevra Therapeutics pay a dividend?
Zevra Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Zevra Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures